Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice

Hui-Ching Wang, Tsung-Jang Yeh, Leong-Perng Chan, Chin-Mu Hsu, Shih-Feng Cho, Hui-Ching Wang, Tsung-Jang Yeh, Leong-Perng Chan, Chin-Mu Hsu, Shih-Feng Cho

Abstract

Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive behavior and resistance to conventional intensive chemotherapy. The combination of targeted therapy and conventional chemotherapy has significantly improved clinical outcomes. In recent years, the development of immunotherapies, such as immune checkpoint inhibitors (ICIs), has further increased treatment responses and prolonged survival. However, the limited response rate, risk of immunotherapy-related adverse effects and high cost of immunotherapy make the identification of predictive markers to optimize treatment efficacy a critical issue. Biomarkers are biological molecules that have been widely utilized to predict treatment response to certain treatments and clinical outcomes or to detect disease. An ideal biomarker should exhibit good predictive ability, which can guide healthcare professionals to achieve optimal treatment goals and bring clinical benefit to patients. In this review, we summarized the results of recent and important studies focused on HNSCC ICI immunotherapy and discussed potential biomarkers including their strengths and limitations, aiming to gain more insight into HNSCC immunotherapy in real world clinical practice.

Keywords: biomarker; head and neck cancer; immune checkpoint inhibitor; immunotherapy.

Conflict of interest statement

The authors have no competing interest.

Figures

Figure 1
Figure 1
Current and emerging biomarkers for prediction of the clinical efficacy of immune checkpoint inhibitors (ICIs) in head and neck squamous cell carcinoma (HNSCC). Several host- or tumor-related markers have been demonstrated to be able to predict the clinical efficacy of ICI treatment. Advances in molecular analysis have also provided valuable predictive information such as tumor mutational burden (TMB) and status of microsatellite instability (MSI). Other markers, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and gut or oral cavity microbiota are also being investigated. CTC, circulating tumor cells; ctDNA, circulating tumor DNA; HNSCC, head and neck squamous cell carcinoma; ICIs, immune checkpoint inhibitors; MSI, microsatellite instability; TMB, tumor mutational burden.

References

    1. Haddad R.I., Shin D.M. Recent advances in head and neck cancer. N. Engl. J. Med. 2008;359:1143–1154. doi: 10.1056/NEJMra0707975.
    1. Lo Nigro C., Denaro N., Merlotti A., Merlano M. Head and neck cancer: Improving outcomes with a multidisciplinary approach. Cancer Manag. Res. 2017;9:363–371. doi: 10.2147/CMAR.S115761.
    1. Blanchard P., Baujat B., Holostenco V., Bourredjem A., Baey C., Bourhis J., Pignon J.P. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother. Oncol. 2011;100:33–40. doi: 10.1016/j.radonc.2011.05.036.
    1. Forastiere A.A., Zhang Q., Weber R.S., Maor M.H., Goepfert H., Pajak T.F., Morrison W., Glisson B., Trotti A., Ridge J.A., et al. Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J. Clin. Oncol. 2013;31:845–852. doi: 10.1200/JCO.2012.43.6097.
    1. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008;359:1116–1127. doi: 10.1056/NEJMoa0802656.
    1. Guigay J., Fayette J., Mesia R., Lafond C., Saada-Bouzid E., Geoffrois L., Martin L., Cupissol D., Capitain O., Castanie H., et al. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) J. Clin. Oncol. 2019;37:6002. doi: 10.1200/JCO.2019.37.15_suppl.6002.
    1. Wei S.C., Duffy C.R., Allison J.P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8:1069–1086. doi: 10.1158/-18-0367.
    1. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2015;372:2521–2532. doi: 10.1056/NEJMoa1503093.
    1. Burtness B., Harrington K.J., Greil R., Soulieres D., Tahara M., de Castro G., Jr., Psyrri A., Baste N., Neupane P., Bratland A., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 2019;394:1915–1928. doi: 10.1016/S0140-6736(19)32591-7.
    1. Gandhi L., Rodriguez-Abreu D., Gadgeel S., Esteban E., Felip E., De Angelis F., Domine M., Clingan P., Hochmair M.J., Powell S.F., et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018;378:2078–2092. doi: 10.1056/NEJMoa1801005.
    1. Ferris R.L., Blumenschein G., Jr., Fayette J., Guigay J., Colevas A.D., Licitra L., Harrington K., Kasper S., Vokes E.E., Even C., et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 2016;375:1856–1867. doi: 10.1056/NEJMoa1602252.
    1. Harrington K.J., Ferris R.L., Blumenschein G., Jr., Colevas A.D., Fayette J., Licitra L., Kasper S., Even C., Vokes E.E., Worden F., et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104–1115. doi: 10.1016/S1470-2045(17)30421-7.
    1. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science. 2015;348:56–61. doi: 10.1126/science.aaa8172.
    1. Darvin P., Toor S.M., Nair V.S., Elkord E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med. 2018;50:165. doi: 10.1038/s12276-018-0191-1.
    1. Verma V., Sprave T., Haque W., Simone C.B., Chang J.Y., Welsh J.W., Thomas C.R., Jr. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J. Immunother. Cancer. 2018;6:128. doi: 10.1186/s40425-018-0442-7.
    1. Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y., et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 2019;16:563–580. doi: 10.1038/s41571-019-0218-0.
    1. Bajwa R., Cheema A., Khan T., Amirpour A., Paul A., Chaughtai S., Patel S., Patel T., Bramson J., Gupta V., et al. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study. J. Clin. Med. Res. 2019;11:225–236. doi: 10.14740/jocmr3750.
    1. Califf R.M. Biomarker definitions and their applications. Exp. Biol. Med. 2018;243:213–221. doi: 10.1177/1535370217750088.
    1. Sawyers C.L. The cancer biomarker problem. Nature. 2008;452:548–552. doi: 10.1038/nature06913.
    1. Goossens N., Nakagawa S., Sun X., Hoshida Y. Cancer biomarker discovery and validation. Transl. Cancer Res. 2015;4:256–269. doi: 10.3978/j.issn.2218-676X.2015.06.04.
    1. Hsieh J.C., Wang H.M., Wu M.H., Chang K.P., Chang P.H., Liao C.T., Liau C.T. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. Head Neck. 2019;41:19–45. doi: 10.1002/hed.25932.
    1. Chung C.H., Ely K., McGavran L., Varella-Garcia M., Parker J., Parker N., Jarrett C., Carter J., Murphy B.A., Netterville J., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 2006;24:4170–4176. doi: 10.1200/JCO.2006.07.2587.
    1. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., Fu K.K., Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–7356.
    1. Semrau R., Duerbaum H., Temming S., Huebbers C., Stenner M., Drebber U., Klussmann J.P., Muller R.P., Preuss S.F. Prognostic impact of human papillomavirus status, survivin, and epidermal growth factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer. Head Neck. 2013;35:1339–1344. doi: 10.1002/hed.23126.
    1. Young R.J., Rischin D., Fisher R., McArthur G.A., Fox S.B., Peters L.J., Corry J., Lim A., Waldeck K., Solomon B. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomark. Prev. 2011;20:1230–1237. doi: 10.1158/1055-9965.EPI-10-1262.
    1. Rasmussen J.H., Hakansson K., Rasmussen G.B., Vogelius I.R., Friborg J., Fischer B.M., Bentzen S.M., Specht L. A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. Oral Oncol. 2018;81:52–60. doi: 10.1016/j.oraloncology.2018.04.009.
    1. Albers A.E., Qian X., Kaufmann A.M., Coordes A. Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. Sci. Rep. 2017;7:16715. doi: 10.1038/s41598-017-16918-w.
    1. Zhang W., Edwards A., Fang Z., Flemington E.K., Zhang K. Integrative Genomics and Transcriptomics Analysis Reveals Potential Mechanisms for Favorable Prognosis of Patients with HPV-Positive Head and Neck Carcinomas. Sci. Rep. 2016;6:24927. doi: 10.1038/srep24927.
    1. Fakhry C., Westra W.H., Li S., Cmelak A., Ridge J.A., Pinto H., Forastiere A., Gillison M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 2008;100:261–269. doi: 10.1093/jnci/djn011.
    1. Yu Z., Weinberger P.M., Haffty B.G., Sasaki C., Zerillo C., Joe J., Kowalski D., Dziura J., Camp R.L., Rimm D.L., et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 2005;11:1160–1166.
    1. Zhao Y., Yu D., Li H., Nie P., Zhu Y., Liu S., Zhu M., Fang B. Cyclin D1 overexpression is associated with poor clinicopathological outcome and survival in oral squamous cell carcinoma in Asian populations: Insights from a meta-analysis. PLoS ONE. 2014;9:e93210. doi: 10.1371/journal.pone.0093210.
    1. Gallo O., Boddi V., Calzolari A., Simonetti L., Trovati M., Bianchi S. bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin. Cancer Res. 1996;2:261–267.
    1. Lo Muzio L., Falaschini S., Farina A., Rubini C., Pezzetti F., Campisi G., De Rosa G., Capogreco M., Carinci F. Bcl-2 as prognostic factor in head and neck squamous cell carcinoma. Oncol. Res. 2005;15:249–255. doi: 10.3727/096504005776404599.
    1. Bauman J.E., Austin M.C., Schmidt R., Kurland B.F., Vaezi A., Hayes D.N., Mendez E., Parvathaneni U., Chai X., Sampath S., et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: Results from a randomised, phase II trial. Br. J. Cancer. 2013;109:2096–2105. doi: 10.1038/bjc.2013.576.
    1. Hayes M., Lan C., Yan J., Xie Y., Gray T., Amirkhan R.H., Dowell J.E. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res. 2011;31:4135–4139.
    1. Rodrigo J.P., Garcia L.A., Ramos S., Lazo P.S., Suarez C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2000;6:3177–3182.
    1. Dubot C., Bernard V., Sablin M.P., Vacher S., Chemlali W., Schnitzler A., Pierron G., Rais K.A., Bessoltane N., Jeannot E., et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur. J. Cancer. 2018;91:47–55. doi: 10.1016/j.ejca.2017.12.016.
    1. Ishiguro R., Fujii M., Yamashita T., Tashiro M., Tomita T., Ogawa K., Kameyama K. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma. Anticancer Res. 2003;23:5213–5220.
    1. Caponio V.C.A., Troiano G., Adipietro I., Zhurakivska K., Arena C., Mangieri D., Mascitti M., Cirillo N., Lo Muzio L. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer. Br. J. Cancer. 2020 doi: 10.1038/s41416-020-0984-6.
    1. Nelson M.H., Diven M.A., Huff L.W., Paulos C.M. Harnessing the Microbiome to Enhance Cancer Immunotherapy. J. Immunol. Res. 2015;2015:368736. doi: 10.1155/2015/368736.
    1. Yu T., Guo F., Yu Y., Sun T., Ma D., Han J., Qian Y., Kryczek I., Sun D., Nagarsheth N., et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017;170:548–563. doi: 10.1016/j.cell.2017.07.008.
    1. Oliva M., Spreafico A., Taberna M., Alemany L., Coburn B., Mesia R., Siu L. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann. Oncol. 2019;30:57–67. doi: 10.1093/annonc/mdy507.
    1. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012;12:252–264. doi: 10.1038/nrc3239.
    1. Zhang J., Bu X., Wang H., Zhu Y., Geng Y., Nihira N.T., Tan Y., Ci Y., Wu F., Dai X., et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–95. doi: 10.1038/nature25015.
    1. Ngamphaiboon N., Chureemas T., Siripoon T., Arsa L., Trachu N., Jiarpinitnun C., Pattaranutaporn P., Sirachainan E., Larbcharoensub N. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Med. Oncol. 2019;36:21. doi: 10.1007/s12032-018-1241-1.
    1. Muller T., Braun M., Dietrich D., Aktekin S., Hoft S., Kristiansen G., Goke F., Schrock A., Bragelmann J., Held S.A.E., et al. PD-L1: A novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget. 2017;8:52889–52900. doi: 10.18632/oncotarget.17547.
    1. Okada S., Itoh K., Ishihara S., Shimada J., Kato D., Tsunezuka H., Miyata N., Hirano S., Teramukai S., Inoue M. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma. Surg. Oncol. 2018;27:259–265. doi: 10.1016/j.suronc.2018.04.007.
    1. Hansen A.R., Siu L.L. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. JAMA Oncol. 2016;2:15–16. doi: 10.1001/jamaoncol.2015.4685.
    1. Motzer R.J., Tannir N.M., McDermott D.F., Frontera O.A., Melichar B., Choueiri T.K., Plimack E.R., Barthelemy P., Porta C., George S., et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2018;378:1277–1290. doi: 10.1056/NEJMoa1712126.
    1. Segal N.H., Ou S.I., Balmanoukian A., Fury M.G., Massarelli E., Brahmer J.R., Weiss J., Schoffski P., Antonia S.J., Massard C., et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase I/II expansion cohort. Eur. J. Cancer. 2019;109:154–161. doi: 10.1016/j.ejca.2018.12.029.
    1. Cohen E.E.W., Soulieres D., Le Tourneau C., Dinis J., Licitra L., Ahn M.J., Soria A., Machiels J.P., Mach N., Mehra R., et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet. 2019;393:156–167. doi: 10.1016/S0140-6736(18)31999-8.
    1. Reck M., Rodriguez-Abreu D., Robinson A.G., Hui R., Csoszi T., Fulop A., Gottfried M., Peled N., Tafreshi A., Cuffe S., et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016;375:1823–1833. doi: 10.1056/NEJMoa1606774.
    1. Zandberg D.P., Algazi A.P., Jimeno A., Good J.S., Fayette J., Bouganim N., Ready N.E., Clement P.M., Even C., Jang R.W., et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur. J. Cancer. 2019;107:142–152. doi: 10.1016/j.ejca.2018.11.015.
    1. Ferris R.L., Blumenschein G., Jr., Fayette J., Guigay J., Colevas A.D., Licitra L., Harrington K.J., Kasper S., Vokes E.E., Even C., et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45–51. doi: 10.1016/j.oraloncology.2018.04.008.
    1. Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582. doi: 10.1038/nature14129.
    1. Lui V.W., Hedberg M.L., Li H., Vangara B.S., Pendleton K., Zeng Y., Lu Y., Zhang Q., Du Y., Gilbert B.R., et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3:761–769. doi: 10.1158/-13-0103.
    1. Leduc C., Adam J., Louvet E., Sourisseau T., Dorvault N., Bernard M., Maingot E., Faivre L., Cassin-Kuo M.S., Boissier E., et al. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open. 2018;3:e000257. doi: 10.1136/esmoopen-2017-000257.
    1. Cimino-Mathews A., Thompson E., Taube J.M., Ye X., Lu Y., Meeker A., Xu H., Sharma R., Lecksell K., Cornish T.C., et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum. Pathol. 2016;47:52–63. doi: 10.1016/j.humpath.2015.09.003.
    1. Takamori S., Toyokawa G., Okamoto I., Takada K., Kozuma Y., Matsubara T., Haratake N., Akamine T., Katsura M., Mukae N., et al. Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer. Anticancer Res. 2017;37:4223–4228. doi: 10.21873/anticanres.11813.
    1. Jie H.B., Gildener-Leapman N., Li J., Srivastava R.M., Gibson S.P., Whiteside T.L., Ferris R.L. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br. J. Cancer. 2013;109:2629–2635. doi: 10.1038/bjc.2013.645.
    1. Mattox A.K., Lee J., Westra W.H., Pierce R.H., Ghossein R., Faquin W.C., Diefenbach T.J., Morris L.G., Lin D.T., Wirth L.J., et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4(+) TILs in the Presence of PD-L1(+) TAMs. Cancer Res. 2017;77:6365–6374. doi: 10.1158/0008-5472.CAN-16-3453.
    1. Cohen E.E.W., Bell R.B., Bifulco C.B., Burtness B., Gillison M.L., Harrington K.J., Le Q.T., Lee N.Y., Leidner R., Lewis R.L., et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) J. Immunother. Cancer. 2019;7:184. doi: 10.1186/s40425-019-0662-5.
    1. Koppel C., Schwellenbach H., Zielinski D., Eckstein S., Martin-Ortega M., D’Arrigo C., Schildhaus H.U., Ruschoff J., Jasani B. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Mod. Pathol. 2018;31:1630–1644. doi: 10.1038/s41379-018-0071-1.
    1. Sunshine J.C., Nguyen P.L., Kaunitz G.J., Cottrell T.R., Berry S., Esandrio J., Xu H., Ogurtsova A., Bleich K.B., Cornish T.C., et al. PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clin. Cancer Res. 2017;23:4938–4944. doi: 10.1158/1078-0432.CCR-16-1821.
    1. Ionescu D.N., Downes M.R., Christofides A., Tsao M.S. Harmonization of PD-L1 testing in oncology: A Canadian pathology perspective. Curr. Oncol. 2018;25:e209–e216. doi: 10.3747/co.25.4031.
    1. Wang H.C., Chan L.P., Cho S.F. Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma. Front. Oncol. 2019;9:1084. doi: 10.3389/fonc.2019.01084.
    1. Partlova S., Boucek J., Kloudova K., Lukesova E., Zabrodsky M., Grega M., Fucikova J., Truxova I., Tachezy R., Spisek R., et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology. 2015;4:e965570. doi: 10.4161/21624011.2014.965570.
    1. Wang J., Sun H., Zeng Q., Guo X.J., Wang H., Liu H.H., Dong Z.Y. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci. Rep. 2019;9:13404. doi: 10.1038/s41598-019-49771-0.
    1. Lechner A., Schlosser H.A., Thelen M., Wennhold K., Rothschild S.I., Gilles R., Quaas A., Siefer O.G., Huebbers C.U., Cukuroglu E., et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. Oncoimmunology. 2019;8:1535293. doi: 10.1080/2162402X.2018.1535293.
    1. Kim H.R., Ha S.J., Hong M.H., Heo S.J., Koh Y.W., Choi E.C., Kim E.K., Pyo K.H., Jung I., Seo D., et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci. Rep. 2016;6:36956. doi: 10.1038/srep36956.
    1. Mandal R., Senbabaoglu Y., Desrichard A., Havel J.J., Dalin M.G., Riaz N., Lee K.W., Ganly I., Hakimi A.A., Chan T.A., et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1:e89829. doi: 10.1172/jci.insight.89829.
    1. Chow L.Q.M., Haddad R., Gupta S., Mahipal A., Mehra R., Tahara M., Berger R., Eder J.P., Burtness B., Lee S.H., et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J. Clin. Oncol. 2016;34:3838–3845. doi: 10.1200/JCO.2016.68.1478.
    1. Bauml J., Seiwert T.Y., Pfister D.G., Worden F., Liu S.V., Gilbert J., Saba N.F., Weiss J., Wirth L., Sukari A., et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J. Clin. Oncol. 2017;35:1542–1549. doi: 10.1200/JCO.2016.70.1524.
    1. Colevas A.D., Bahleda R., Braiteh F., Balmanoukian A., Brana I., Chau N.G., Sarkar I., Molinero L., Grossman W., Kabbinavar F., et al. Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial. Ann. Oncol. 2018;29:2247–2253. doi: 10.1093/annonc/mdy411.
    1. Henderson S., Chakravarthy A., Su X., Boshoff C., Fenton T.R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014;7:1833–1841. doi: 10.1016/j.celrep.2014.05.012.
    1. Cannataro V.L., Gaffney S.G., Sasaki T., Issaeva N., Grewal N.K.S., Grandis J.R., Yarbrough W.G., Burtness B., Anderson K.S., Townsend J.P. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene. 2019;38:3475–3487. doi: 10.1038/s41388-018-0657-6.
    1. Faden D.L., Thomas S., Cantalupo P.G., Agrawal N., Myers J., DeRisi J. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma. Oral Oncol. 2017;74:8–14. doi: 10.1016/j.oraloncology.2017.09.002.
    1. Faden D.L., Ding F., Lin Y., Zhai S., Kuo F., Chan T.A., Morris L.G., Ferris R.L. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Oral Oncol. 2019;96:140–147. doi: 10.1016/j.oraloncology.2019.07.020.
    1. McGranahan N., Furness A.J., Rosenthal R., Ramskov S., Lyngaa R., Saini S.K., Jamal-Hanjani M., Wilson G.A., Birkbak N.J., Hiley C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–1469. doi: 10.1126/science.aaf1490.
    1. Yarchoan M., Hopkins A., Jaffee E.M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N. Engl. J. Med. 2017;377:2500–2501. doi: 10.1056/NEJMc1713444.
    1. Hellmann M.D., Ciuleanu T.E., Pluzanski A., Lee J.S., Otterson G.A., Audigier-Valette C., Minenza E., Linardou H., Burgers S., Salman P., et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N. Engl. J. Med. 2018;378:2093–2104. doi: 10.1056/NEJMoa1801946.
    1. Seiwert T.Y., Haddad R., Bauml J., Weiss J., Pfister D.G., Gupta S., Mehra R., Gluck I., Kang H., Worden F., et al. Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC) Cancer Res. 2018;78:LB-339. doi: 10.1158/1538-7445.am2018-lb-339.
    1. Cristescu R., Mogg R., Ayers M., Albright A., Murphy E., Yearley J., Sher X., Liu X.Q., Lu H., Nebozhyn M., et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362 doi: 10.1126/science.aar3593.
    1. Hanna G.J., Lizotte P., Cavanaugh M., Kuo F.C., Shivdasani P., Frieden A., Chau N.G., Schoenfeld J.D., Lorch J.H., Uppaluri R., et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018;3 doi: 10.1172/jci.insight.98811.
    1. Li W., Wildsmith S., Ye J., Si H., Morsli N., He P., Shetty J., Yovine A.J., Holoweckyj N., Raja R., et al. Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure. J. Clin. Oncol. 2020;38:6511. doi: 10.1200/JCO.2020.38.15_suppl.6511.
    1. Hladikova K., Koucky V., Boucek J., Laco J., Grega M., Hodek M., Zabrodsky M., Vosmik M., Rozkosova K., Vosmikova H., et al. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J. Immunother. Cancer. 2019;7:261. doi: 10.1186/s40425-019-0726-6.
    1. Galon J., Fox B.A., Bifulco C.B., Masucci G., Rau T., Botti G., Marincola F.M., Ciliberto G., Pages F., Ascierto P.A., et al. Immunoscore and Immunoprofiling in cancer: An update from the melanoma and immunotherapy bridge 2015. J. Transl. Med. 2016;14:273. doi: 10.1186/s12967-016-1029-z.
    1. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi: 10.1126/science.1129139.
    1. Donnem T., Hald S.M., Paulsen E.E., Richardsen E., Al-Saad S., Kilvaer T.K., Brustugun O.T., Helland A., Lund-Iversen M., Poehl M., et al. Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer. Clin. Cancer Res. 2015;21:2635–2643. doi: 10.1158/1078-0432.CCR-14-1905.
    1. Zhang X.M., Song L.J., Shen J., Yue H., Han Y.Q., Yang C.L., Liu S.Y., Deng J.W., Jiang Y., Fu G.H., et al. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. Hum. Pathol. 2018;82:104–112. doi: 10.1016/j.humpath.2018.07.012.
    1. Lechner A., Schlosser H., Rothschild S.I., Thelen M., Reuter S., Zentis P., Shimabukuro-Vornhagen A., Theurich S., Wennhold K., Garcia-Marquez M., et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget. 2017;8:44418–44433. doi: 10.18632/oncotarget.17901.
    1. Anderson A.C., Joller N., Kuchroo V.K. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44:989–1004. doi: 10.1016/j.immuni.2016.05.001.
    1. Koyama S., Akbay E.A., Li Y.Y., Herter-Sprie G.S., Buczkowski K.A., Richards W.G., Gandhi L., Redig A.J., Rodig S.J., Asahina H., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 2016;7:10501. doi: 10.1038/ncomms10501.
    1. Thommen D.S., Schreiner J., Muller P., Herzig P., Roller A., Belousov A., Umana P., Pisa P., Klein C., Bacac M., et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunol. Res. 2015;3:1344–1355. doi: 10.1158/2326-6066.CIR-15-0097.
    1. Chauvin J.M., Pagliano O., Fourcade J., Sun Z., Wang H., Sander C., Kirkwood J.M., Chen T.H., Maurer M., Korman A.J., et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J. Clin. Investig. 2015;125:2046–2058. doi: 10.1172/JCI80445.
    1. Jenkins R.W., Barbie D.A., Flaherty K.T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer. 2018;118:9–16. doi: 10.1038/bjc.2017.434.
    1. Haddad R., Concha-Benavente F., Blumenschein G., Jr., Fayette J., Guigay J., Colevas A.D., Licitra L., Kasper S., Vokes E.E., Worden F., et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019;125:3208–3218. doi: 10.1002/cncr.32190.
    1. Jamieson N.B., Maker A.V. Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther. 2017;24:134–140. doi: 10.1038/cgt.2016.63.
    1. Prat A., Navarro A., Pare L., Reguart N., Galvan P., Pascual T., Martinez A., Nuciforo P., Comerma L., Alos L., et al. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Res. 2017;77:3540–3550. doi: 10.1158/0008-5472.CAN-16-3556.
    1. Seiwert T.Y., Burtness B., Mehra R., Weiss J., Berger R., Eder J.P., Heath K., McClanahan T., Lunceford J., Gause C., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–965. doi: 10.1016/S1470-2045(16)30066-3.
    1. Hernandez C.P., Morrow K., Velasco C., Wyczechowska D.D., Naura A.S., Rodriguez P.C. Effects of cigarette smoke extract on primary activated T cells. Cell. Immunol. 2013;282:38–43. doi: 10.1016/j.cellimm.2013.04.005.
    1. Desrichard A., Kuo F., Chowell D., Lee K.W., Riaz N., Wong R.J., Chan T.A., Morris L.G.T. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. J. Natl. Cancer Inst. 2018;110:1386–1392. doi: 10.1093/jnci/djy060.
    1. Gildener-Leapman N., Ferris R.L., Bauman J.E. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 2013;49:1089–1096. doi: 10.1016/j.oraloncology.2013.09.009.
    1. Le D.T., Durham J.N., Smith K.N., Wang H., Bartlett B.R., Aulakh L.K., Lu S., Kemberling H., Wilt C., Luber B.S., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733.
    1. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015;372:2509–2520. doi: 10.1056/NEJMoa1500596.
    1. Martens A., Wistuba-Hamprecht K., Foppen M.G., Yuan J., Postow M.A., Wong P., Romano E., Khammari A., Dreno B., Capone M., et al. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin. Cancer Res. 2016;22:2908–2918. doi: 10.1158/1078-0432.CCR-15-2412.
    1. Tardy M.P., Di Mauro I., Ebran N., Refae S., Bozec A., Benezery K., Peyrade F., Guigay J., Sudaka-Bahadoran A., Badoual C., et al. Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma. Oral Oncol. 2018;80:104–107. doi: 10.1016/j.oraloncology.2018.04.001.
    1. Luchini C., Bibeau F., Ligtenberg M.J.L., Singh N., Nottegar A., Bosse T., Miller R., Riaz N., Douillard J.Y., Andre F., et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann. Oncol. 2019;30:1232–1243. doi: 10.1093/annonc/mdz116.
    1. Zavridou M., Mastoraki S., Strati A., Koutsodontis G., Klinakis A., Psyrri A., Lianidou E. Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma. Sci. Rep. 2020;10:6551. doi: 10.1038/s41598-020-63055-y.
    1. Tada H., Takahashi H., Kuwabara-Yokobori Y., Shino M., Chikamatsu K. Molecular profiling of circulating tumor cells predicts clinical outcome in head and neck squamous cell carcinoma. Oral Oncol. 2020;102:104558. doi: 10.1016/j.oraloncology.2019.104558.
    1. Economopoulou P., Kotsantis I., Kyrodimos E., Lianidou E.S., Psyrri A. Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs) Oral Oncol. 2017;74:83–89. doi: 10.1016/j.oraloncology.2017.09.012.
    1. Misawa K., Imai A., Matsui H., Kanai A., Misawa Y., Mochizuki D., Mima M., Yamada S., Kurokawa T., Nakagawa T., et al. Identification of novel methylation markers in HPV-associated oropharyngeal cancer: Genome-wide discovery, tissue verification and validation testing in ctDNA. Oncogene. 2020;39:4741–4755. doi: 10.1038/s41388-020-1327-z.
    1. Bratman S.V., Yang S.C., Iafolla M.A., Liu Z., Hansen A.R., Bedard P.L., Lheureux S., Spreafico A., Razak A.A., Shchegrova S. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer. 2020;1:873–881. doi: 10.1038/s43018-020-0096-5.
    1. Xun Y., Cao Q., Zhang J., Guan B., Wang M. Clinicopathological and prognostic significance of circulating tumor cells in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 2020;104:104638. doi: 10.1016/j.oraloncology.2020.104638.
    1. Liu K., Chen N., Wei J., Ma L., Yang S., Zhang X. Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma. Oncol. Rep. 2020;43:1525–1535. doi: 10.3892/or.2020.7536.
    1. Alix-Panabieres C. The future of liquid biopsy. Nature. 2020;579:S9. doi: 10.1038/d41586-020-00844-5.
    1. Tinhofer I., Konschak R., Stromberger C., Raguse J.D., Dreyer J.H., Johrens K., Keilholz U., Budach V. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 2014;25:2042–2047. doi: 10.1093/annonc/mdu271.
    1. Grobe A., Blessmann M., Hanken H., Friedrich R.E., Schon G., Wikner J., Effenberger K.E., Kluwe L., Heiland M., Pantel K., et al. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin. Cancer Res. 2014;20:425–433. doi: 10.1158/1078-0432.CCR-13-1101.
    1. Wang H.M., Wu M.H., Chang P.H., Lin H.C., Liao C.D., Wu S.M., Hung T.M., Lin C.Y., Chang T.C., Tzu-Tsen Y., et al. The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer. Head Neck. 2019;41:2676–2687. doi: 10.1002/hed.25744.
    1. Strati A., Koutsodontis G., Papaxoinis G., Angelidis I., Zavridou M., Economopoulou P., Kotsantis I., Avgeris M., Mazel M., Perisanidis C., et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann. Oncol. 2017;28:1923–1933. doi: 10.1093/annonc/mdx206.
    1. Rao V.U., Arakeri G., Subash A., Bagadia R.K., Thakur S., Kudpaje A.S., Nayar R., Patil S., Paiva Fonseca F., Gomez R.S., et al. Circulating tumour cells in head and neck cancers: Biological insights. J. Oral Pathol. Med. 2020 doi: 10.1111/jop.13075.
    1. Chang P.H., Wu M.H., Liu S.Y., Wang H.M., Huang W.K., Liao C.T., Yen T.C., Ng S.H., Chen J.S., Lin Y.C., et al. The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing. Cancers. 2019;11:540. doi: 10.3390/cancers11040540.
    1. Guibert N., Delaunay M., Lusque A., Boubekeur N., Rouquette I., Clermont E., Mourlanette J., Gouin S., Dormoy I., Favre G., et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–112. doi: 10.1016/j.lungcan.2018.04.001.
    1. Nicolazzo C., Raimondi C., Mancini M., Caponnetto S., Gradilone A., Gandini O., Mastromartino M., Del Bene G., Prete A., Longo F., et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep. 2016;6:31726. doi: 10.1038/srep31726.
    1. Dhar M., Wong J., Che J., Matsumoto M., Grogan T., Elashoff D., Garon E.B., Goldman J.W., Sollier Christen E., Di Carlo D., et al. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci. Rep. 2018;8:2592. doi: 10.1038/s41598-018-19245-w.
    1. Roy S., Trinchieri G. Microbiota: A key orchestrator of cancer therapy. Nat. Rev. Cancer. 2017;17:271–285. doi: 10.1038/nrc.2017.13.
    1. Greenhill C. Gut microbiota: Anti-cancer therapies affected by gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 2014;11:1. doi: 10.1038/nrgastro.2013.238.
    1. Kroemer G., Zitvogel L. Cancer immunotherapy in 2017: The breakthrough of the microbiota. Nat. Rev. Immunol. 2018;18:87–88. doi: 10.1038/nri.2018.4.
    1. Brandi G., Frega G. Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. Int. J. Mol. Sci. 2019;20:2699. doi: 10.3390/ijms20112699.
    1. Gopalakrishnan V., Spencer C.N., Nezi L., Reuben A., Andrews M.C., Karpinets T.V., Prieto P.A., Vicente D., Hoffman K., Wei S.C., et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. doi: 10.1126/science.aan4236.
    1. Le Bars P., Matamoros S., Montassier E., Le Vacon F., Potel G., Soueidan A., Jordana F., de La Cochetiere M.F. The oral cavity microbiota: Between health, oral disease, and cancers of the aerodigestive tract. Can. J. Microbiol. 2017;63:475–492. doi: 10.1139/cjm-2016-0603.
    1. Pushalkar S., Ji X., Li Y., Estilo C., Yegnanarayana R., Singh B., Li X., Saxena D. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol. 2012;12:144. doi: 10.1186/1471-2180-12-144.
    1. Hooper S.J., Wilson M.J., Crean S.J. Exploring the link between microorganisms and oral cancer: A systematic review of the literature. Head Neck. 2009;31:1228–1239. doi: 10.1002/hed.21140.
    1. Shin J.M., Luo T., Kamarajan P., Fenno J.C., Rickard A.H., Kapila Y.L. Microbial Communities Associated with Primary and Metastatic Head and Neck Squamous Cell Carcinoma—A High Fusobacterial and Low Streptococcal Signature. Sci. Rep. 2017;7:9934. doi: 10.1038/s41598-017-09786-x.
    1. Ferris R.L., Blumenschein G., Harrington K., Fayette J., Guigay J., Colevas A.D., Licitra L., Vokes E., Gillison M., Even C., et al. Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141. Cancer Res. 2017;77:CT022. doi: 10.1158/1538-7445.am2017-ct022.
    1. Ho B.X., Pek N.M.Q., Soh B.-S. Disease modeling using 3D organoids derived from human induced pluripotent stem cells. Int. J. Mol. Sci. 2018;19:936. doi: 10.3390/ijms19040936.
    1. Dutta D., Heo I., Clevers H. Disease Modeling in Stem Cell-Derived 3D Organoid Systems. Trends Mol. Med. 2017;23:393–410. doi: 10.1016/j.molmed.2017.02.007.
    1. Neal J.T., Li X., Zhu J., Giangarra V., Grzeskowiak C.L., Ju J., Liu I.H., Chiou S.H., Salahudeen A.A., Smith A.R., et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175:1972–1988. doi: 10.1016/j.cell.2018.11.021.
    1. Yuki K., Cheng N., Nakano M., Kuo C.J. Organoid Models of Tumor Immunology. Trends Immunol. 2020;41:652–664. doi: 10.1016/j.it.2020.06.010.
    1. Scognamiglio G., De Chiara A., Parafioriti A., Armiraglio E., Fazioli F., Gallo M., Aversa L., Camerlingo R., Cacciatore F., Colella G., et al. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br. J. Cancer. 2019;121:979–982. doi: 10.1038/s41416-019-0616-1.
    1. Driehuis E., Kolders S., Spelier S., Lõhmussaar K., Willems S., Devriese L., de Bree R., de Ruiter E., Korving J., Begthel H. Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov. 2019;9:852–871. doi: 10.1158/-18-1522.
    1. Lee J.S., Ruppin E. Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. JAMA Oncol. 2019 doi: 10.1001/jamaoncol.2019.2311.
    1. Trebeschi S., Drago S.G., Birkbak N.J., Kurilova I., Calin A.M., Pizzi A.D., Lalezari F., Lambregts D.M.J., Rohaan M.W., Parmar C., et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann. Oncol. 2019;30:998–1004. doi: 10.1093/annonc/mdz108.
    1. Yu K.H., Beam A.L., Kohane I.S. Artificial intelligence in healthcare. Nat. Biomed. Eng. 2018;2:719–731. doi: 10.1038/s41551-018-0305-z.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅